| 产品分类 |
货号 |
产品名称 |
靶点 |
|
ADC |
CHB273 |
Anti-ALCAM/CD166 Reference
Antibody (praluzatamab ravtansine) |
ALCAM / CD166 |
|
ADC |
CHB274 |
Anti-ALCAM / CD166
Reference Antibody (Praluzatamab-MMAE) |
ALCAM / CD166 |
|
ADC |
CHB289 |
Anti-AMHR2 Reference
Antibody (Murlentamab-MMAE) |
AMHR2 |
|
ADC |
CHB227 |
Anti-AXL / UFO Reference
Antibody (Tilvestamab-MMAE) |
AXL / UFO |
|
ADC |
CHB258 |
Anti-AXL / UFO Reference
Antibody (Enapotamab vedotin) |
AXL / UFO |
|
ADC |
CHB269 |
Anti-MUC16 Reference
Antibody (oregovomab-MMAE) |
CA125 / MUC16 |
|
ADC |
CHB320 |
Anti-MUC16 Reference
Antibody (Sofituzumab vedotin) |
CA125 / MUC16 |
|
ADC |
CHB293 |
Anti-CA9 / CAIX Reference
Antibody (girentuximab-MMAE) |
CA9 / Carbonic anhydrase 9
|
|
ADC |
CHB315 |
Anti-CanAg Reference
Antibody (Cantuzumab mertansine) |
CanAg |
|
ADC |
CHB316 |
Anti-CanAg Reference
Antibody (Cantuzumab ravtansine) |
CanAg |
|
ADC |
CHB259 |
Anti-CD19 Reference
Antibody (denintuzumab-MMAF) |
CD19 |
|
ADC |
CHB256 |
Anti-CD79b Reference
Antibody (Polatuzumab vedotin-piiq) |
CD79b |
|
ADC |
CHB317 |
Anti-CD79b Reference
Antibody (iladatuzumab vedotin) |
CD79b |
|
ADC |
CHB262 |
Anti-CEACAM5 / CEA / CD66e
Reference Antibody (labetuzumab govitecan) |
CEACAM5 / CEA / CD66e |
|
ADC |
CHB275 |
Anti-CEACAM5 / CEA / CD66e
Reference Antibody (Tusamitamab ravtansine) |
CEACAM5 / CEA / CD66e |
|
ADC |
CHB276 |
Anti-CEACAM5 / CEA / CD66e
Reference Antibody (Tusamitamab-MMAE) |
CEACAM5 / CEA / CD66e |
|
ADC |
CHB578 |
Anti-CLDN18.2 Reference
Antibody (zolbetuximab MMAE) |
CLDN18.2 |
|
ADC |
CHB286 |
Anti-CXCR4/CD184 Reference
Antibody (ulocuplumab-MMAE) |
CXCR4 / CD184 |
|
ADC |
CHB294 |
Anti-DLL3 Reference
Antibody (rovalpituzumab-MMAE) |
DLL3 |
|
ADC |
CHB290 |
Anti-Endoglin / CD105
Reference Antibody (carotuximab-MMAE) |
Endoglin / CD105 |
|
ADC |
CHB267 |
Anti-ERBB1 / EGFR / HER1
Reference Antibody (Depatuxizumab mafodotin) |
ERBB1 / EGFR / HER1 |
|
ADC |
CHB299 |
Anti-ERBB1 / EGFR / HER1
Reference Antibody (Cetuximab-MMAE) |
ERBB1 / EGFR / HER1 |
|
ADC |
CHB321 |
Anti-ERBB1 / EGFR / HER1
Reference Antibody (Laprituximab emtansine) |
ERBB1 / EGFR / HER1 |
|
ADC |
CHB253 |
Anti-ERBB2 / HER2 / CD340
Reference Antibody (Disitamab vedotin) |
ERBB2 / HER2 / CD340 |
|
ADC |
CHB279 |
Anti-ERBB2 / HER2 / CD340
Reference Antibody (Trastuzumab emtansine) |
ERBB2 / HER2 / CD340 |
|
ADC |
CHB280 |
Anti-ERBB2 / HER2 / CD340
Reference Antibody (Trastuzumab-MMAE) |
ERBB2 / HER2 / CD340 |
|
ADC |
CHB268 |
Anti-ERBB3/ HER3 Reference
Antibody (patritumab-MMAE) |
ERBB3 / HER3 |
|
ADC |
CHB298 |
Anti-ERBB3/ HER3 Reference
Antibody (Patritumab deruxtecan) |
ERBB3 / HER3 |
|
ADC |
CHB284 |
Anti-FOLH1 / PSMA
Reference Antibody (rosopatamab-MMAE) |
FOLH1 / PSMA |
|
ADC |
CHB271 |
Anti-FOLR1 / FRA Reference
Antibody (Mirvetuximab soravtansine) |
FOLR1 / FRA |
|
ADC |
CHB285 |
Anti-FOLR1 / FRA Reference
Antibody (farletuzumab-MMAE) |
FOLR1 / FRA |
|
ADC |
CHB296 |
Anti-FOLR1 / FRA Reference
Antibody (mirvetuximab-MMAE) |
FOLR1 / FRA |
|
ADC |
CHB287 |
Anti-GD3 Reference
Antibody (ecromeximab-MMAE) |
GD3 |
|
ADC |
CHB260 |
Anti-GPNMB Reference
Antibody (Glembatumumab vedotin) |
GPNMB |
|
ADC |
CHB261 |
Anti-GUCY2C Reference
Antibody (Indusatumab vedotin) |
GUCY2C |
|
ADC |
CHB249 |
Anti-HGFR / c-Met
Reference Antibody (Telisotuzumab vedotin) |
HGFR / c-Met |
|
ADC |
CHB001-1 |
IgG1 / Kappa Isotype
Control（
MMAE
）
|
HIV |
|
ADC |
CHB292 |
Anti-IL-3Ra / CD123
Reference Antibody (talacotuzumab-MMAE) |
IL-3Ra / CD123 |
|
ADC |
CHB250 |
Anti-LIV-1 / SLC39A6
Reference Antibody (Ladiratuzumab vedotin) |
LIV-1 / SLC39A6 |
|
ADC |
CHB277 |
Anti-Mesothelin Reference
Antibody (anetumab ravtansine) |
Mesothelin |
|
ADC |
CHB278 |
Anti-Mesothelin Reference
Antibody (anetumab-MMAE) |
Mesothelin |
|
ADC |
CHB648 |
Anti-MMAE |
MMAE |
|
ADC |
CHB288 |
Anti-MU5AC Reference
Antibody (ensituximab-MMAE) |
MU5AC |
|
ADC |
CHB291 |
Anti-MUC1 Reference
Antibody (clivatuzumab-MMAE) |
MUC1 |
|
ADC |
CHB263 |
Anti-NaPi2b / SLC34A2
Reference Antibody (Lifastuzumab vedotin) |
NaPi2b / SLC34A2 |
|
ADC |
CHB281 |
Anti-NCAM1 / CD56
Reference Antibody (lorvotuzumab mertansine) |
NCAM1 / CD56 |
|
ADC |
CHB282 |
Anti-NCAM1 / CD56
Reference Antibody (lorvotuzumab-MMAE) |
NCAM1 / CD56 |
|
ADC |
CHB248 |
Anti-Nectin-4 Reference
Antibody (enfortumab vedotin-ejfv) |
Nectin-4 |
|
ADC |
CHB266 |
Anti-ROR1 Reference
Antibody (Zilovertamab vedotin) |
ROR1 |
|
ADC |
CHB264 |
Anti-ROR2 Reference
Antibody (ozuriftamab vedotin) |
ROR2 |
|
ADC |
CHB265 |
Anti-Siglec-2 / CD22
Reference Antibody (Pinatuzumab vedotin) |
Siglec-2 / CD22 |
|
ADC |
CHB301 |
Anti-Siglec-2 / CD22
Reference Antibody (inotuzumab-MMAE) |
Siglec-2 / CD22 |
|
ADC |
CHB319 |
Anti-SLITRK6 Reference
Antibody (Sirtratumab vedotin) |
SLITRK6 |
|
ADC |
CHB257 |
Anti-TF / Factor III /
Tissue Factor / CD142 Reference Antibody (tisotumab vedotin) |
TF / Factor III / Tissue
Factor / CD142 |
|
ADC |
CHB252 |
Anti-TNFRSF8 / CD30
Reference Antibody (brentuximab vedotin) |
TNFRSF8 / CD30 |
|
ADC |
CHB318 |
Anti-TNFSF7 / CD27L / CD70
Reference Antibody (Vorsetuzumab mafodotin) |
TNFSF7 / CD27L / CD70 |
|
ADC |
CHB270 |
Anti-TROP2 Reference
Antibody (datopotamab deruxtecan) |
TROP2 |
|
ADC |
CHB295 |
Anti-TROP2 Reference
Antibody (Sacituzumab-MMAE) |
TROP2 |